感染症体外診断薬市場：製品、技術、適応症、エンドユーザー別-2025-2030年世界予測

感染症体外診断薬市場は、2023年に490億6,000万米ドルと評価され、2024年には525億1,000万米ドルに達すると予測され、CAGR 7.22%で成長し、2030年には799億5,000万米ドルに達すると予測されています。

感染症体外診断薬（IVD）市場の範囲は、人体内の感染症を検出するために血液、組織、その他の体液などのサンプルに対して実施される診断テストを包含します。この市場は、世界の感染症流行の増加、迅速な診断ソリューションに対する需要の増加、COVID-19のようなパンデミックの脅威の継続により、必要不可欠なものとなっています。これらの診断薬はタイムリーで正確な診断に不可欠であり、適切な治療計画と管理を促進し、その結果、人命を救い、疾病の蔓延を抑制します。最終用途には、HIV、インフルエンザ、結核、肝炎、新興感染症などの検査が含まれ、病院、臨床検査室、ポイントオブケアなどがあります。市場成長は、精度とスピードの向上につながる次世代シーケンシング、PCR、イムノアッセイなどの技術進歩に大きく影響されています。診断結果を解釈するためのAIや機械学習の斬新な利用もまた、注目すべき機会を提示しています。さらに、利便性、結果の即時解釈、プライバシーに後押しされた在宅検査重視の高まりは、この業界において重要なニッチを切り開きつつあります。しかし、先進的な診断薬の高価格、規制上のハードル、新興国地域の限られたヘルスケア・インフラといった課題が、市場の拡大を抑制しています。また、特定の検査における技術的限界に起因する信頼性の低い結果が抑止力となることもあります。技術革新の鍵となる分野は、手頃な価格で簡便かつ高感度な携帯型診断薬の開発にあります。このような技術革新は、特に世界の低資源環境におけるアクセシビリティを劇的に向上させることができます。また、新規疾患のバイオマーカー探索や、複数の病原体を同時にターゲットとするマルチプレックス検査の拡大も、ゲームチェンジャーとなり得る。この市場の性質は、新たな感染脅威の頻繁な出現によって非常にダイナミックに変化するため、継続的な研究開発投資と、熟練した対応力を維持するためのテクノロジープロバイダーとヘルスケア専門家の協力が必要となります。市場機会を生かすための提言としては、より効果的で安価な診断薬を開発するための戦略的パートナーシップや研究開発への堅実な投資などが挙げられます。

市場力学：急速に進化する感染症体外診断薬市場の主要市場インサイトを公開

感染症体外診断薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 感染症の流行と定期的発生の増加
  • 感染症診断のための迅速検査キットの採用増加
  • ウイルス性疾患を抑制するための政府のイニシアチブの実施
• 市場抑制要因
  • 感染症体外診断用医薬品のリコール
• 市場機会
  • ゲノミクスとプロテオミクスの進歩
  • 新しい体外診断用医薬品を発売するための研究開発投資の増加
• 市場の課題
  • 感染症体外診断薬キットの入手可能性の制限

ポーターの5つの力：感染症体外診断薬市場をナビゲートする戦略的ツール

ポーターの5つの力フレームワークは、感染症体外診断薬市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：感染症体外診断薬市場における外部からの影響の把握

外部マクロ環境要因は、感染症体外診断薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析感染症体外診断薬市場における競合情勢の把握

感染症体外診断薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス感染症体外診断薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、感染症体外診断薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 感染症の蔓延と定期的な流行の増加
    • 感染症の診断における迅速検査キットの導入増加
    • ウイルス性疾患の抑制に向けた政府の取り組みの実施
  • 抑制要因
    • 感染症体外診断用製品のリコール
  • 機会
    • ゲノミクスとプロテオミクスの進歩
    • 新しいIVD製品の発売に向けて研究開発への投資を増加
  • 課題
    • 感染症体外診断薬キットのアクセス制限
• 市場セグメンテーション分析
  • 製品：感染性病原体の検査のための高度な試薬の需要の高まり
  • 技術：HIVや肝炎感染などのウイルス量を迅速に検出し定量化するための分子診断技術の採用拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境
• 顧客のカスタマイズ

第6章 感染症体外診断薬市場：製品別

• 機器
• 試薬
• ソフトウェア

第7章 感染症体外診断薬市場：技術別

• 免疫化学
• 微生物学
• 分子診断

第8章 感染症体外診断薬市場適応症別

• カンジダ症
• クラミジア
• クロストリジウム・ディフィシル
• クリエイティブ
• 胃腸炎
• 淋病
• 肝炎
• HIV
• HPV
• MRSA
• 呼吸器ウイルス
• 連鎖球菌
• 結核と薬剤耐性結核
• ＶＲＥ

第9章 感染症体外診断薬市場：エンドユーザー別

• 学術調査機関
• 診断検査室
• 病院・クリニック

第10章 南北アメリカの感染症体外診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の感染症体外診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの感染症体外診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ロシュ、分子診断における臨床ニーズの向上と公衆衛生の課題への対応を目指して次世代Qpcrシステムを発表
  • バイオケアメディカル、信頼性、精度、一貫性のある熱誘導エピトープ回収（HIER）を実現する新しいIVD抗原回収チャンバーARCの発売を発表
  • 免疫組織化学用の新しい試薬ソリューション「Optimer-Fc」の発売
  • DxLabはトースターサイズの箱で、感染症や有害病原体の検査室品質の検出を実現します

企業一覧

• Trinity Biotech PLC
• Qiagen N.V.
• DiaSorin S.p.A
• Koninklijke Philips N.V.
• Vela Diagnostics
• InBios International, Inc.
• PerkinElmer, Inc.
• Quest Diagnostics
• F. Hoffmann La-Roche Ltd.
• bioMerieux SA
• Laboratory Corporation Of America Holdings
• Sysmex Corporation
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• Grifols, S.A.
• Hologic, Inc.
• Siemens Healthineers AG
• Danaher Corporation
• Quidel Corporation
• Epitope Diagnostics, Inc.
• Genspeed Biotech GmbH
• Meril Life Sciences Pvt. Ltd.
• Abbott Laboratories
• Uniogen Oy
• DX Lab Inc.
• Illumina, Inc.
• OraSure Technologies, Inc.
• Merck KGaA
• Becton, Dickinson and Company

LIST OF FIGURES

• FIGURE 1. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CRE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GASTROENTERITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HPV, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MRSA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY RESPIRATORY VIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STREPTOCOCCUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TB AND DRUG-RESISTANT TB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VRE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 49. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 70. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 71. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 74. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 75. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 82. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 83. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 87. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 91. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 94. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 95. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 98. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 99. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 102. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 103. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 104. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 106. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 107. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 108. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 111. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 114. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 115. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 118. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 119. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 120. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 123. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 124. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 127. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 128. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 131. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 132. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 135. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 136. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 139. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 140. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 143. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 144. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 147. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 148. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 149. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. NIGERIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 151. NIGERIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 152. NIGERIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 153. NIGERIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. NORWAY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 155. NORWAY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 156. NORWAY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 157. NORWAY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. POLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 159. POLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 160. POLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 161. POLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 163. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 164. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 165. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 167. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 168. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 169. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 171. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 172. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 173. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 175. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 176. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 177. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 179. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 180. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 181. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. SWEDEN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 183. SWEDEN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 184. SWEDEN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 185. SWEDEN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. SWITZERLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 187. SWITZERLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 188. SWITZERLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 189. SWITZERLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 190. TURKEY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 191. TURKEY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 192. TURKEY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 193. TURKEY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 195. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 196. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 197. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 198. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 199. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 200. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 201. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 202. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 203. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Infectious Diseases In-Vitro Diagnostics Market was valued at USD 49.06 billion in 2023, expected to reach USD 52.51 billion in 2024, and is projected to grow at a CAGR of 7.22%, to USD 79.95 billion by 2030.

The scope of the infectious diseases in-vitro diagnostics (IVD) market encompasses diagnostic tests performed on samples such as blood, tissue, and other body fluids to detect infectious diseases within the human body. This market has become essential due to rising global infectious disease prevalence, increasing demand for rapid diagnostic solutions, and the ongoing threat of pandemics like COVID-19. These diagnostics are imperative for timely and accurate diagnosis, facilitating proper treatment plans and management, thus saving lives and curbing disease spread. Key applications involve testing for diseases such as HIV, influenza, tuberculosis, hepatitis, and emerging infections, with end-use sectors including hospitals, clinical laboratories, and point-of-care settings. Market growth is significantly influenced by technological advancements like next-generation sequencing, PCR, and immunoassays leading to improved accuracy and speed. The novel use of AI and machine learning for interpreting diagnostic results also presents noteworthy opportunities. Furthermore, the growing emphasis on home testing, fueled by convenience, immediate result interpretation, and privacy, is carving a significant niche within this industry. However, challenges such as high costs of advanced diagnostics, regulatory hurdles, and limited healthcare infrastructure in developing regions restrain market expansion. Also, unreliable results due to technical limitations in specific tests can be a deterrent. A key area for innovation lies in the development of affordable, simple, yet highly sensitive portable diagnostics. These innovations can dramatically enhance accessibility, particularly in low-resource settings worldwide. Also, exploring biomarkers for novel diseases and expanding multiplex testing, which simultaneously targets multiple pathogens, can be game-changers. The nature of this market is highly dynamic, driven by the frequent emergence of new infectious threats, thus requiring continuous R&D investment and collaboration between technology providers and healthcare professionals to stay adept and responsive. Recommendations for capitalizing on market opportunities include strategic partnerships and robust investments in R&D to cultivate more effective, less expensive diagnostics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Infectious Diseases In-Vitro Diagnostics Market

The Infectious Diseases In-Vitro Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing Prevalence and Periodic Outbreak of Infectious Diseases
  • Rising Adoption of Rapid Test Kits for Diagnosis of Infectious Diseases
  • Implementation of Government Initiatives to Curb Viral Diseases
• Market Restraints
  • Product Recalls of Infectious Disease In-vitro Diagnostics
• Market Opportunities
  • Advancements in Genomics and Proteomics
  • Increasing Investments in R&D to Launch New IVD Products
• Market Challenges
  • Limited Accessibility of Infectious Diseases In-vitro Diagnostics Kits

Porter's Five Forces: A Strategic Tool for Navigating the Infectious Diseases In-Vitro Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Infectious Diseases In-Vitro Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Infectious Diseases In-Vitro Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Infectious Diseases In-Vitro Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Infectious Diseases In-Vitro Diagnostics Market

A detailed market share analysis in the Infectious Diseases In-Vitro Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Infectious Diseases In-Vitro Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Infectious Diseases In-Vitro Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Infectious Diseases In-Vitro Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Trinity Biotech PLC, Qiagen N.V., DiaSorin S.p.A, Koninklijke Philips N.V., Vela Diagnostics, InBios International, Inc., PerkinElmer, Inc., Quest Diagnostics, F. Hoffmann La-Roche Ltd., bioMerieux SA, Laboratory Corporation Of America Holdings, Sysmex Corporation, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Grifols, S.A., Hologic, Inc., Siemens Healthineers AG, Danaher Corporation, Quidel Corporation, Epitope Diagnostics, Inc., Genspeed Biotech GmbH, Meril Life Sciences Pvt. Ltd., Abbott Laboratories, Uniogen Oy, DX Lab Inc., Illumina, Inc., OraSure Technologies, Inc., Merck KGaA, and Becton, Dickinson and Company.

Market Segmentation & Coverage

This research report categorizes the Infectious Diseases In-Vitro Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Instruments, Reagents, and Software.
• Based on Technology, market is studied across Immunochemistry, Microbiology, and Molecular Diagnostics.
• Based on Indication, market is studied across Candidiasis, Chlamydia, Clostridium difficile, CRE, Gastroenteritis, Gonorrhea, Hepatitis, HIV, HPV, MRSA, Respiratory Virus, Streptococcus, TB and Drug-resistant TB, and VRE.
• Based on End-user, market is studied across Academic Research Institutes, Diagnostic Laboratories, and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing Prevalence and Periodic Outbreak of Infectious Diseases
    • 5.1.1.2. Rising Adoption of Rapid Test Kits for Diagnosis of Infectious Diseases
    • 5.1.1.3. Implementation of Government Initiatives to Curb Viral Diseases
  • 5.1.2. Restraints
    • 5.1.2.1. Product Recalls of Infectious Disease In-vitro Diagnostics
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in Genomics and Proteomics
    • 5.1.3.2. Increasing Investments in R&D to Launch New IVD Products
  • 5.1.4. Challenges
    • 5.1.4.1. Limited Accessibility of Infectious Diseases In-vitro Diagnostics Kits
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Rising demand for advanced reagents for testing infectious pathogens
  • 5.2.2. Technology: Expanding adoption of molecular diagnostics technology to quickly detect and quantify viral load, such as in HIV or hepatitis infections
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Infectious Diseases In-Vitro Diagnostics Market, by Product

• 6.1. Introduction
• 6.2. Instruments
• 6.3. Reagents
• 6.4. Software

7. Infectious Diseases In-Vitro Diagnostics Market, by Technology

• 7.1. Introduction
• 7.2. Immunochemistry
• 7.3. Microbiology
• 7.4. Molecular Diagnostics

8. Infectious Diseases In-Vitro Diagnostics Market, by Indication

• 8.1. Introduction
• 8.2. Candidiasis
• 8.3. Chlamydia
• 8.4. Clostridium difficile
• 8.5. CRE
• 8.6. Gastroenteritis
• 8.7. Gonorrhea
• 8.8. Hepatitis
• 8.9. HIV
• 8.10. HPV
• 8.11. MRSA
• 8.12. Respiratory Virus
• 8.13. Streptococcus
• 8.14. TB and Drug-resistant TB
• 8.15. VRE

9. Infectious Diseases In-Vitro Diagnostics Market, by End-user

• 9.1. Introduction
• 9.2. Academic Research Institutes
• 9.3. Diagnostic Laboratories
• 9.4. Hospitals & Clinics

10. Americas Infectious Diseases In-Vitro Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Infectious Diseases In-Vitro Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Infectious Diseases In-Vitro Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Roche Launches Next-Generation Qpcr System to Advance Clinical Needs In Molecular Diagnostics and Address Public Health Challenges
  • 13.3.2. Biocare Medical Announces the Launch of ARC: The New IVD Antigen Retrieval Chamber for Reliable, Precise and Consistent Heat Induced Epitope Retrieval (HIER)
  • 13.3.3. Launch of Optimer-Fc as a New Reagent Solution for Immunohistochemistry
  • 13.3.4. DxLab Delivers Lab-Quality Detection of Infectious Diseases and Harmful Pathogens in a Toaster-Size Box

Companies Mentioned

• 1. Trinity Biotech PLC
• 2. Qiagen N.V.
• 3. DiaSorin S.p.A
• 4. Koninklijke Philips N.V.
• 5. Vela Diagnostics
• 6. InBios International, Inc.
• 7. PerkinElmer, Inc.
• 8. Quest Diagnostics
• 9. F. Hoffmann La-Roche Ltd.
• 10. bioMerieux SA
• 11. Laboratory Corporation Of America Holdings
• 12. Sysmex Corporation
• 13. Bio-Rad Laboratories, Inc.
• 14. Thermo Fisher Scientific Inc.
• 15. Grifols, S.A.
• 16. Hologic, Inc.
• 17. Siemens Healthineers AG
• 18. Danaher Corporation
• 19. Quidel Corporation
• 20. Epitope Diagnostics, Inc.
• 21. Genspeed Biotech GmbH
• 22. Meril Life Sciences Pvt. Ltd.
• 23. Abbott Laboratories
• 24. Uniogen Oy
• 25. DX Lab Inc.
• 26. Illumina, Inc.
• 27. OraSure Technologies, Inc.
• 28. Merck KGaA
• 29. Becton, Dickinson and Company